- Syngeneic models offer a ready-to-test platform to screen the efficacy of the test compounds in vivo on standard murine cancer cell lines.
- The host immunity and transplanted cancer cells are from the same host and share the same genetic background. These models help to understand the tumour microenvironment and metastasis during cancer development. They enable the screening of the test compound’s therapeutic effect in an active immune system.
- These models are highly effective for studying immuno-therapies involving immune checkpoint inhibitors and immunocyte recruitment at the tumour site.
- Deliverables and Readouts: Tumour volume, tumour growth inhibition, body weight, clinical signs.
- Timelines: 50-60 days (total in life phase)
In vivo oncology: Syngeneic models
|Tumour type||Cell line||Origin||Test species||Model type|
|Breast||4T1||Mouse||Mouse||Subcutaneous & Orthotopic|
|E3||Mouse||Mouse||Subcutaneous & Orthotopic|
|Bladder||NBT-II||Rat||Rat||Subcutaneous & Orthotopic|